Teclistamab for Relapsed or Refractory Multiple Myeloma

Usmani S, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021; 398(10301):665-674. DOI: 10.1016/S0140-6736(21)01338-6. View

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

Moreau P, van de Donk N, Delforge M, Einsele H, De Stefano V, Perrot A . Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. Adv Ther. 2023; 40(5):2412-2425. PMC: 10129954. DOI: 10.1007/s12325-023-02480-7. View